SEC For	rm 4 FORM	4	UNITEI	D ST/	٩ΤΕ	s s	ECL						GE C	оммі	SSION				
Section 16. Form 4 or Form 5 obligations may continue. See					ed pur	Washington, D.C. 20549 NT OF CHANGES IN BENEFICIAL OWNE ad pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Estim	Numbe	verage burde	3235-0287
1. Name and Address of Reporting Person [*] Mates Sharon						2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]									elationship eck all applie X Directo	able)	eporting Person(s) to Issue e) 10% Own		
(Last) (First) (Middle) C/O INTRA-CELLULAR THERAPIES, INC.						3. Date of Earliest Transaction (Month/Day/Year) 04/24/2024									X Officer (give title Other (specify below) Chairman and CEO				
430 EAST 29TH STREET (Street) NEW YORK NY 10016				- 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S		(Zip)			Che sati	ck this sfy the a	box to ind affirmative	icate that a defense o	a trans onditio	ons of Rule	made 10b5-	e pursuar -1(c). Se	e Instructio			plan th	at is intende	d to
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D)					sactior	n	2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3,		d (A) or	5. Amou Securitie Benefici Owned F	nt of es ally following	Form (D) of	vnership 1: Direct r Indirect 1str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amoun	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 04/24					4/202	2024			М		8,63	8,638 A		\$16.8	6 1,05	1,058,947		D	
Common	Stock		Table II -	Deriva		Sec						f, or				0,329		D	
1. Title of Derivative Security (Instr. 3)	of 2. 3. Transaction 3A. Deemed ve Conversion Date Execution Date y or Exercise (Month/Day/Year) if any		d Date,	4. Transa	ransaction code (Instr.)		umber ivative urities uired or oosed D) (Instr. and 5)		sable and) of Securities Underlying Derivative Sec (Instr. 3 and 4) (Instr. 3 and 4)		Amount es Security d 4) Amount or Number	8. Price of Derivative Security (Instr. 5) 9. Numb derivative Benefici Owned Followin Reported Transact (Instr. 4)		e s illy g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi (Instr. 4)		

Stock Option (right to buy) \$17.57 04/24/2024

04/24/2024

Explanation of Responses:

\$16.86

Stock Option (right to buy)

1. This option was granted on June 30, 2014 with an exercise price of \$16.86 per share and will expire on June 30, 2024. All shares underlying this option have vested.

2. This option was granted on January 2, 2015 with an exercise price of \$17.57 per share and will expire on January 2, 2025. All shares underlying this option have vested.

<u>/s/ Lawrence J. Hineline,</u> Attorney-in-fact	04/25/2024			
** Signature of Reporting Person	Date			

8,638

11,382

\$<mark>0</mark>

\$<mark>0</mark>

0

216,998

D

D

Common Stock

Common Stock

06/30/2024

01/02/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

М

Μ

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

8,638

11,382

(1)

(2)